229 related articles for article (PubMed ID: 9212478)
41. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.
Ahmedzai S; Brooks D
J Pain Symptom Manage; 1997 May; 13(5):254-61. PubMed ID: 9185430
[TBL] [Abstract][Full Text] [Related]
42. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
43. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L; Hays H; Jensen NH; de Waroux BL; Bolt M; Donald R; Kalso E
BMJ; 2001 May; 322(7295):1154-8. PubMed ID: 11348910
[TBL] [Abstract][Full Text] [Related]
44. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature.
Tassinari D; Sartori S; Tamburini E; Scarpi E; Raffaeli W; Tombesi P; Maltoni M
J Palliat Med; 2008 Apr; 11(3):492-501. PubMed ID: 18363493
[TBL] [Abstract][Full Text] [Related]
45. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
46. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain.
Elsner F; Radbruch L; Loick G; Gaertner J; Sabatowski R
J Palliat Med; 2005 Aug; 8(4):743-50. PubMed ID: 16128648
[TBL] [Abstract][Full Text] [Related]
47. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
[TBL] [Abstract][Full Text] [Related]
48. [Efficacy and safety of transdermal fentanyl patches for opioid initiation in patients with gastrointestinal obstruction].
Miyoshi T; Yamauchi H; Misumi N; Goto T; Kai S; Yoshida E; Nishino T; Hasuo Y
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1401-5. PubMed ID: 25434443
[TBL] [Abstract][Full Text] [Related]
49. [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
Zhen ZJ; Sun XF; Xia Y; Ling JY; Zheng L; Luo WB; Lin H
Ai Zheng; 2007 Aug; 26(8):866-9. PubMed ID: 17697549
[TBL] [Abstract][Full Text] [Related]
50. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
51. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
[TBL] [Abstract][Full Text] [Related]
52. Transdermal opioids for cancer pain.
Skaer TL
Health Qual Life Outcomes; 2006 Mar; 4():24. PubMed ID: 16573839
[TBL] [Abstract][Full Text] [Related]
53. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Hanks GW; Nugent M; Higgs CM; Busch MA;
Palliat Med; 2004 Dec; 18(8):698-704. PubMed ID: 15623166
[TBL] [Abstract][Full Text] [Related]
54. Treatment of cancer pain with transdermal fentanyl.
Gourlay GK
Lancet Oncol; 2001 Mar; 2(3):165-72. PubMed ID: 11902567
[TBL] [Abstract][Full Text] [Related]
55. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery.
Minkowitz HS; Rathmell JP; Vallow S; Gargiulo K; Damaraju CV; Hewitt DJ
Pain Med; 2007; 8(8):657-68. PubMed ID: 18028044
[TBL] [Abstract][Full Text] [Related]
57. Oral transmucosal fentanyl: new preparation. For breakthrough cancer pain when morphine fails.
Prescrire Int; 2002 Aug; 11(60):106-7. PubMed ID: 12199262
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
[TBL] [Abstract][Full Text] [Related]
59. Breakthrough strong opioid analgesia prescription in patients using transdermal fentanyl admitted to a hospice.
Lawrie I; Lloyd-Williams M; Waterhouse E
Am J Hosp Palliat Care; 2003; 20(3):229-30. PubMed ID: 12785045
[TBL] [Abstract][Full Text] [Related]
60. Transdermal opioids for cancer pain control in patients with renal impairment.
Melilli G; Samolsky Dekel BG; Frenquelli C; Mellone R; Pannuti F
J Opioid Manag; 2014; 10(2):85-93. PubMed ID: 24715663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
